Crit Care Explor. 2020 Nov 03;2(11):e0245. doi: 10.1097/CCE.0000000000000245. eCollection 2020 Nov.
Effects of a Clonidine Taper on Dexmedetomidine Use and Withdrawal in Adult Critically Ill Patients-A Pilot Study.
Critical care explorations
Krupa Bhatt, Ashley Thompson Quan, Laura Baumgartner, Shawn Jia, Rhiannon Croci, Kathleen Puntillo, James Ramsay, Rima H Bouajram
Affiliations
Affiliations
- Department of Pharmacy, Scripps Memorial Hospital La Jolla, La Jolla, CA.
- Department of Pharmaceutical Services, University of California, San Francisco Medical Center, San Francisco, CA.
- Department of Clinical Pharmacy, Touro University California College of Pharmacy, Vallejo, CA.
- Department of Anesthesiology, University of North Carolina, Chapel Hill, NC.
PMID: 33163969
PMCID: PMC7641427 DOI: 10.1097/CCE.0000000000000245
Abstract
OBJECTIVES: Prolonged use of dexmedetomidine has become increasingly common due to its favorable sedative and anxiolytic properties. Hypersympathetic withdrawal symptoms have been reported with abrupt discontinuation of prolonged dexmedetomidine infusions. Clonidine has been used to transition patients off dexmedetomidine infusions for ICU sedation. The objective of this study was to compare the occurrence of dexmedetomidine withdrawal symptoms in ICU patients transitioning to a clonidine taper versus those weaned off dexmedetomidine alone after prolonged dexmedetomidine infusion.
DESIGN: This was a single-center, prospective, double cohort observational study conducted from November 2017 to December 2018.
SETTING: Medical-surgical, cardiothoracic, and neurosurgical ICUs in a tertiary care hospital.
PATIENTS: We included adult ICU patients being weaned off dexmedetomidine after receiving continuous infusions for at least 3 days.
INTERVENTIONS: Patients were either weaned off dexmedetomidine alone or with a clonidine taper at the discretion of the providers.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was the incidence of at least two dexmedetomidine withdrawal symptoms during a single assessment within 24 hours of dexmedetomidine discontinuation. Time on dexmedetomidine after wean initiation and difference in medication cost were also evaluated. Forty-two patients were included in this study: 15 received clonidine (Group C) and 27 weaned off dexmedetomidine alone (Group D). There was no significant difference in the incidence of two or more withdrawal symptoms between groups (73% in Group C vs 59% in Group D;
CONCLUSIONS: Our study demonstrated that patients receiving clonidine were able to wean off dexmedetomidine more rapidly, with a considerable cost savings and no difference in dexmedetomidine withdrawal symptoms, compared with patients weaned off dexmedetomidine alone. Clonidine may be a safe, effective, and practical option to transition patients off prolonged dexmedetomidine infusions.
Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.
Keywords: adrenergic alpha-2 receptor agonists; clonidine; dexmedetomidine; hypnotics and sedatives; substance withdrawal syndrome; symptom assessment
Conflict of interest statement
The authors have disclosed that they do not have any potential conflicts of interest.
References
- J Neurosurg Anesthesiol. 2014 Jul;26(3):192-7 - PubMed
- Crit Care Explor. 2019 Aug 09;1(8):e0035 - PubMed
- Pediatr Crit Care Med. 2018 Apr;19(4):287-297 - PubMed
- Crit Care Med. 2018 Sep;46(9):e825-e873 - PubMed
- J Vasc Interv Radiol. 2013 Jun;24(6):779-86 - PubMed
- J Pediatr Pharmacol Ther. 2010 Jan;15(1):38-42 - PubMed
- Pain. 2012 Jan;153(1):142-8 - PubMed
- JAMA. 2009 Feb 4;301(5):489-99 - PubMed
- Pediatr Crit Care Med. 2010 Jan;11(1):e1-3 - PubMed
- J Pediatr Pharmacol Ther. 2019 Jan-Feb;24(1):16-21 - PubMed
- SAGE Open Med. 2015 Dec 15;3:2050312115621767 - PubMed
- Brain Dev. 2016 Aug;38(7):648-53 - PubMed
- Anesth Analg. 2009 Feb;108(2):631-4 - PubMed
- J Clin Anesth. 1994 Sep-Oct;6(5):430-3 - PubMed
- Hum Exp Toxicol. 2013 Jan;32(1):107-10 - PubMed
- Pediatr Crit Care Med. 2014 Oct;15(8):706-14 - PubMed
- J Neurosurg Anesthesiol. 2016 Jan;28(1):14-20 - PubMed
- Can J Hosp Pharm. 2013 Jan;66(1):21-7 - PubMed
- Crit Care Med. 2013 Jan;41(1):263-306 - PubMed
- Eur J Anaesthesiol. 2015 Nov;32(11):805-11 - PubMed
- Am J Crit Care. 2019 Sep;28(5):361-369 - PubMed
- Pharmacotherapy. 2015 Mar;35(3):251-9 - PubMed
- Paediatr Anaesth. 2008 Jan;18(1):87-8 - PubMed
- J Pediatr Pharmacol Ther. 2010 Jan;15(1):4-9 - PubMed
- Acta Anaesthesiol Belg. 2003;54(3):227-32 - PubMed
- J Pediatr Pharmacol Ther. 2015 Jan-Feb;20(1):45-53 - PubMed
- Front Pharmacol. 2018 Jan 04;8:940 - PubMed
- J Anesth. 2014 Feb;28(1):38-50 - PubMed
- Intensive Care Med. 2012 Feb;38(2):300-7 - PubMed
- JAMA. 2007 Dec 12;298(22):2644-53 - PubMed
- Pediatr Crit Care Med. 2008 Nov;9(6):573-80 - PubMed
Publication Types